

November 11, 2020

To,  
The Corporate Relations Department  
The BSE Limited  
Department of Corporate Services  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai – 400001.  
**Ref:- Scrip Code:- 500126**

To,  
The Listing Department  
The National Stock Exchange of India Limited  
Exchange Plaza, Plot No. C/1, G Block,  
Bandra Kurla Complex, Bandra (East),  
Mumbai – 400051  
**Ref:- Symbol:- PGHL**

Dear Sir / Madam,

**Sub:- Unaudited Financial Results for the quarter ended September 30, 2020**

We are pleased to inform you that at the meeting of the Board of Directors of the Company held today, the Unaudited Financial Results for the quarter ended September 30, 2020 were approved.

We are enclosing herewith the following:

- a. Unaudited Financial Results for the quarter ended September 30, 2020;
- b. Press Release; and
- c. Limited Review Report in respect of the Unaudited Financial Results for the quarter ended September 30, 2020 furnished by Statutory Auditors of the Company

Kindly take the same on record and oblige.

Thanking you,  
Yours faithfully,

***For Procter & Gamble Health Limited  
(Formerly Merck Limited)***

MILIND VASANT THATTE  
Digitally signed by  
MILIND VASANT  
THATTE  
Date: 2020.11.11  
19:24:36 +05'30'

***Milind Thatte  
Managing Director***

**PROCTER & GAMBLE HEALTH LIMITED**  
**(formerly known as MERCK LIMITED)**

Regd. Office: Godrej One, 8th Floor, Eastern Express Highway, Piroshanagar, Vikhroli (East), Mumbai : 400 079.

CIN No. L99999MH1967PLC013726, email: investorgrievance.im@pg.com

**STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30 SEPTEMBER 2020**

(₹ in lakhs)

Sr. No.	Particulars	(1)	(2)	(3)	(4)
		Three months ended 30th September 2020  Unaudited	Preceding Three months ended 30th June 2020  Audited [Refer note 7]	Corresponding Three months ended 30th September 2019  Unaudited	Eighteen months ended 30th June 2020  Audited
1.	<b>Revenue from Operations</b>	<b>26,397.0</b>	20,115.6	22,516.8	1,35,586.0
2.	<b>Other Income</b>	<b>672.0</b>	1,068.3	672.4	6,889.0
3.	<b>Total income (1+2)</b>	<b>27,069.0</b>	21,183.9	23,189.2	1,42,475.0
4.	<b>Expenses</b>				
	a) Cost of materials consumed	<b>9,305.0</b>	5,277.0	6,381.8	41,609.6
	b) Purchases of stock-in-trade	<b>516.0</b>	213.0	783.0	2,837.4
	c) Changes in inventories of finished goods, work-in-progress and stock in trade	<b>(325.0)</b>	(351.5)	630.7	(1,303.0)
	d) Employee benefits expense	<b>3,869.0</b>	<b>3,556.9</b>	3,026.7	18,293.0
	e) Depreciation and amortisation expense	<b>736.0</b>	804.7	404.9	2,945.0
	f) Finance Costs	<b>24.0</b>	-	-	-
	g) Other expenses	<b>5,222.0</b>	6,111.1	6,704.6	42,608.0
	<b>Total expenses (4)</b>	<b>19,347.0</b>	15,611.2	17,931.7	1,06,990.0
5.	<b>Profit before exceptional items and tax (3-4)</b>	<b>7,722.0</b>	5,572.7	5,257.5	35,485.0
6.	Less: Exceptional items	-	-	-	-
7.	<b>Profit before tax (5-6)</b>	<b>7,722.0</b>	5,572.7	5,257.5	35,485.0
8.	<b>Tax expenses</b>				
	Current Tax	<b>2,034.0</b>	1,571.4	810.0	10,278.0
	Deferred Tax	<b>(93.0)</b>	(84.7)	871.5	599.0
	Tax for earlier years	<b>(145.0)</b>	(800.0)	-	(800.0)
9.	<b>Net Profit for the period (7-8)</b>	<b>5,926.0</b>	4,886.0	3,576.0	25,408.0
10.	<b>Other Comprehensive Income</b>				
	Items that will not be reclassified to profit or loss				
	i. Re-measurement (losses) on defined benefit plans	<b>(27.0)</b>	(309.1)	(50.0)	(1,237.0)
	ii. Income tax effect	<b>7.0</b>	77.4	2.9	311.0
	<b>Total Other Comprehensive Income, net of tax</b>	<b>(20.0)</b>	(231.7)	(47.1)	(926.0)
11.	<b>Total Comprehensive Income for the period (9+10)</b>	<b>5,906.0</b>	4,654.3	3,528.9	24,482.0
12.	Paid-up equity share capital (Face Value Rs 10/- each)	<b>1,660.0</b>	1,660.0	1,660.0	1,660.0
13.	Other equity excluding Revaluation reserve as per Balance sheet	-	-	-	88,974.0
14.	<b>Earnings per equity share (of Rs 10/- each)</b> <b>*(not annualised)</b>				
	(a) Basic and Diluted (in Rs.)	<b>* 35.7</b>	* 29.4	* 21.5	153.1

Notes:

- The above financial results for the quarter ended September 30, 2020 have been reviewed and recommended by the Audit Committee, and approved by the Board of Directors of the Company at its Meeting held on November 11, 2020 and have been subjected to a limited review by the Statutory Auditors of the Company.
- Results for all the above periods are in compliance with Indian Accounting Standards (Ind-AS).
- The Code on Social Security, 2020 ('Code') relating to employee benefits during employment and post-employment benefits received Presidential assent in September 2020. The Code has been published in the Gazette of India. However, the date on which the Code will come into effect has not been notified. The Company will assess the impact of the Code when it comes into effect and will record any related impact in the period the Code becomes effective.
- As a result of the nationwide lockdown imposed by the Government of India in view of the Covid-19 pandemic, the operations of the Company were temporarily disrupted at its manufacturing, warehouse and distribution locations from second half of March 2020. The operations have gradually resumed in a phased manner in line with the Government directives issued from time to time. The Company's Management has evaluated the impact of this pandemic on its business operations and financial position and based on such review, there is no significant impact on the Company's assets, capital and financial resources, profitability parameters or liquidity positions as at September 30, 2020. The Management does not envisage any impact on the going concern assumption in the foreseeable future. However, the impact assessment of COVID-19 will be a continuing process given the uncertainties associated with its progression.
- Effective July 1, 2020, the Company has adopted Ind AS 116, Leases and applied the standard to its Leases using the modified retrospective approach. Accordingly, the Company has not restated comparative information. This has resulted in recognising a lease liability measured at present value of the remaining lease payments and a corresponding Right-of-Use (ROU) asset as if the lease has been commenced w.e.f. 1st July 2020. The Company discounted remaining lease payments using the lessee's incremental borrowing rate as at 1st July 2020. The Company has also elected not to apply the requirements of Ind AS 116 to short term leases and leases for which underlying asset is of low value. In the results for the current period, the nature of expenses in respect of Operating lease has changed from lease rent in previous periods to depreciation cost for the right-of-use asset and finance cost for interest accrued on lease liability. The Company has therefore recognised a lease liability and a corresponding ROU asset as at 1st July 2020. The net impact of this adoption is not material on the results for the period and earnings per share.
- The Company now operates under only one segment i.e. Pharmaceuticals which its continuing operations. Accordingly, no separate segment information has been provided.
- The figures for the preceding three months ended 30th June, 2020 are the balancing figures between the audited figures in respect of the eighteen months ended 30th June, 2020 and the year to date figures upto the fifth quarter of that financial period.
- Previous period figures have been regrouped / reclassified wherever necessary.

For Procter & Gamble Health Limited  
[Formerly known as Merck Limited]

MILIND  
VASANT  
THATTE

Digitally signed  
by MILIND  
VASANT THATTE  
Date: 2020.11.11  
19:19:18 +05'30'

Milind Thatte  
Managing Director  
DIN No.08092990

Place : Mumbai  
Date : 11 November 2020  
Please visit us at our website www.pghealthindia.com



## Procter & Gamble Health Limited Announces First Quarter Results

*Sales up by 17% for quarter ended September 30, 2020*

**Mumbai, Nov 11, 2020:** Procter & Gamble Health Limited (formerly Merck Limited) announced today its financial results for the quarter ended September 30, 2020. The company has recorded a total revenue of ₹264.0 crores, up 17.2% vs. year ago. The Profit After Tax (PAT) was ₹59.3 crores vs. ₹35.8 crores year ago.

**Milind Thatte, Managing Director, Procter & Gamble Health Limited** said, *“With the country still in the midst of the pandemic, we remain focussed on protecting the health and safety of our employees and partners, ensuring uninterrupted supplies of our quality and affordable vitamins, minerals, supplements and medicinal products for our patients and consumers, and on supporting communities and relief efforts.*

*‘Despite tough market conditions, the Company has made a strong recovery in the first quarter delivering a double-digit growth driven by portfolio consumerisation, robust business continuity planning and a phased return-to-work initiative. We are very proud of our teams who have been quick and agile to adapt to the changing environment, embracing virtual mediums to ensure continued connect with HCPs and partners, and stepping up on consumer outreach efforts resulting in a positive brand recall across categories. With ‘SEHAT’ (meaning Health) - our Corporate Social Responsibility (CSR) initiative – the Company continues to step up as a #ForceForGood reaching out to vulnerable populations and supporting relief efforts through partner NGOs.’*

### **About Procter & Gamble Health Limited:**

Procter & Gamble Health Limited (formerly Merck Limited) is one of India’s largest VMS Companies manufacturing and marketing over-the-counter vitamins, minerals, and supplements products for a healthy lifestyle and improved quality of life. Please visit [www.pghealthindia.com](http://www.pghealthindia.com) for the latest news and information about Procter & Gamble Health Limited and its brands.

### **About Procter & Gamble:**

P&G serves consumers around the world with one of the strongest portfolios of trusted, quality, leadership brands, including Always®, Ambi Pur®, Ariel®, Bounty®, Charmin®, Crest®, Dawn®, Downy®, Fairy®, Febreze®, Gain®, Gillette®, Head & Shoulders®, Lenor®, Olay®, Oral-B®, Pampers®, Pantene®, SK-II®, Tide®, Vicks®, and Whisper®. The P&G community includes operations in approximately 70 countries worldwide.

### **CONTACTS**

#### **Media Contacts - Procter & Gamble Health Limited:**

- Ruchita Mehra | [mehra.r@pg.com](mailto:mehra.r@pg.com)
- Paromita Kundu | [kundu.p.1@pg.com](mailto:kundu.p.1@pg.com)

#### **Investor Relations Contact:**

- Flavia Machado | [machado.f.1@pg.com](mailto:machado.f.1@pg.com)

#### **Procter & Gamble Health Limited**

(Formerly known as Merck Limited)

CIN: L99999MH1967PLC013726

Registered Office: Godrej One, 8<sup>th</sup> Floor,

Pirojshanagar, Eastern Express Highway, Vikhroli East,

Mumbai 400 079 | Tel: (91-22) 6866 9000

[www.pghealthindia.com](http://www.pghealthindia.com)

# HARIBHAKTI & CO. LLP

Chartered Accountants

**Independent Auditor's Review Report on quarterly Unaudited Financial Results of Procter & Gamble Health Limited (formerly known as Merck Limited) pursuant to the Regulation 33 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015**

To the Board of Directors

Procter & Gamble Health Limited (formerly known as Merck Limited)

1. We have reviewed the accompanying Statement of Unaudited Financial Results of **Procter & Gamble Health Limited** ("the Company") for the quarter ended 30<sup>th</sup> September, 2020 ("the Statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of the company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the



# HARIBHAKTI & CO. LLP

Chartered Accountants

recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Haribhakti & Co. LLP  
Chartered Accountants  
ICAI Firm Registration No.103523W/W100048



Hemant J. Bhatt  
Partner  
Membership No.: 036834  
UDIN: 20036834AAAAFL4019

Place: Mumbai  
Date: November 11, 2020